Patents by Inventor Pascal Rigollier

Pascal Rigollier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS
    Publication number: 20240366567
    Abstract: The present invention relates to a pharmaceutical combination comprising a KRAS G12C inhibitor and one or more therapeutic agents which is selected from an agent targeting the MARK pathway or an agent targeting parallel pathways; and pharmaceutical compositions comprising the same. The invention also relates to KRAS G12C inhibitors alone or said combinations for use in methods of treating a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutant.
    Type: Application
    Filed: June 23, 2022
    Publication date: November 7, 2024
    Inventors: Saskia Maria BRACHMANN, Simona COTESTA, Xiaoming CUI, Ruben DE KANTER, Anna FARAGO, Marc GERSPACHER, Diana GRAUS PORTA, Jaeyeon KIM, Catherine LEBLANC, Edwige Liliane Jeanne LORTHIOIS, Rainer MACHAUER, Robert MAH, Christophe MURA, Pascal RIGOLLIER, Anirudh Cadapa PRAHALLAD, Nadine SCHNEIDER, Rowan STRINGER, Stefan STUTZ, Andrea VAUPEL, Nicolas WARIN, Rainer WILCKEN, Andreas WEISS
  • PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN
    Publication number: 20240317721
    Abstract: The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, and the therapeutic uses of said compound. The present invention further provides a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: June 22, 2022
    Publication date: September 26, 2024
    Inventors: Claudio BOMIO-CONFAGLIA, Saskia Maria BRACHMANN, Simona COTESTA, Marc GERSPACHER, Catherine LEBLANC, Fabio LIMA, Edwige Liliane Jeanne LORTHIOIS, Rainer MACHAUER, Robert MAH, Sophie RACINE, Pascal RIGOLLIER, Stefan STUTZ, Andrea VAUPEL, Nicolas WARIN, Rainer WILCKEN, Frédéric ZECRI
  • NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND
    Publication number: 20240116900
    Abstract: Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.
    Type: Application
    Filed: October 29, 2021
    Publication date: April 11, 2024
    Inventors: Simona COTESTA, Heng GE, Marc GERSPACHER, Catherine LEBLANC, Bo LIU, Edwige Liliane Jeanne LORTHIOIS, Rainer MACHAUER, Robert MAH, Tanja MEISTER, Christophe MURA, Pascal RIGOLLIER, Nadine SCHNEIDER, Stefan STUTZ, Andrea VAUPEL, Nicolas WARIN, Rainer WILCKEN, Lijun XUE, Marie-Anne LOZAC'H, Ross STRANG
  • PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES OF A KRAS G12C INHIBITOR FOR THE TREATMENT OF CANCERS
    Publication number: 20240082218
    Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.
    Type: Application
    Filed: December 20, 2021
    Publication date: March 14, 2024
    Inventors: Vasileios ASKOXYLAKIS, Saskia Maria BRACHMANN, Simona COTESTA, Xiaoming CUI, Jeffrey ENGELMAN, Anna FARAGO, Marc GERSPACHER, Diana GRAUS PORTA, Catherine LEBLANC, Edwige Liliane Jeanne LORTHIOIS, Bo LIU, Rainer MACHAUER, Robert MAH, Christophe MURA, Pascal RIGOLLIER, Nadine SCHNEIDER, Stefan STUTZ, Andrea Helga Emmi VAUPEL, Nicolas WARIN, Andreas WEISS, Rainer WILCKEN, Padmaja YERRAMILLI-RAO
  • COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS
    Publication number: 20230365571
    Abstract: The present invention relates to tricyclic compounds comprising a diazepinone moiety which are effective in inhibiting Sppl2a (signal peptide peptidase like protease 2a), to pharmaceutical compositions containing such inhibitors, and to methods of using such inhibitors and compositions.
    Type: Application
    Filed: September 15, 2021
    Publication date: November 16, 2023
    Inventors: Trixi Brandl, Claus Ehrhardt, Robert Epple, Christian Markert, Pascal Rigollier, Juraj Velcicky
  • Pyrazolyl derivatives useful as anti-cancer agents
    Patent number: 11702409
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: July 18, 2023
    Assignee: NOVARTIS AG
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • Pyrazolyl derivatives useful as anti-cancer agents
    Publication number: 20220363670
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 17, 2020
    Publication date: November 17, 2022
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • ArylSulfonamide-based matrix metalloprotease inhibitors
    Patent number: 9822092
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: November 21, 2017
    Assignee: NOVARTIS AG
    Inventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael David Shultz, Ruben Alberto Tommasi
  • Organic compounds and their uses
    Patent number: 9206232
    Abstract: The present application describes organic compounds of Formula (II) that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: December 8, 2015
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Arylsulfonamide based matrix metalloprotease inhibitors
    Patent number: 8975439
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: March 10, 2015
    Assignee: Novartis AG
    Inventors: Ruben Alberto Tommasi, Michael David Shultz, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Claus Ehrhardt
  • ArylSulfonamide-Based Matrix Metalloprotease Inhibitors
    Publication number: 20150045398
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Application
    Filed: October 7, 2014
    Publication date: February 12, 2015
    Applicant: NOVARTIS AG
    Inventors: Claus EHRHARDT, Leslie Wighton MCQUIRE, Pascal RIGOLLIER, Olivier ROGEL, Michael David SHULTZ, Ruben Alberto TOMMASI
  • ORGANIC COMPOUNDS AND THEIR USES
    Publication number: 20140357551
    Abstract: The present application describes organic compounds of Formula (II) that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Applicant: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Peptidomimetic sulfamide compounds and antiviral uses thereof
    Patent number: 8840878
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: September 23, 2014
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Peptidomimetic sulfamide compounds and antiviral uses thereof
    Patent number: 8613914
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: December 24, 2013
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Derivatised proline containing peptide compounds as protease inhibitors
    Patent number: 8512690
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: August 20, 2013
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Organic compounds and their uses
    Patent number: 8445527
    Abstract: The present invention provides a method of treating a HCV infection in a subject in need thereof by administering a compound of Formula I: or pharmaceutically acceptable salts thereof or stereoisomers thereof.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: May 21, 2013
    Assignee: Novartis AG
    Inventors: Michael Patane, Prakash Raman, David Thomas Parker, Jiping Fu, Branko Radetich, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng, Trixi Brandl, Francois Lenoir, Pascal Rigollier, Oliver Simic
  • ORGANIC COMPOUNDS AND THEIR USES
    Publication number: 20130034519
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: February 7, 2013
    Inventors: Trixi BRANDL, Prakash RAMAN, Pascal RIGOLLIER, Mohindra SEEPERSAUD, Oliver SIMIC
  • Arylsulfonamide based matrix metalloprotease inhibitors
    Patent number: 8362063
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: January 29, 2013
    Assignee: Novartis AG
    Inventors: Ruben Alberto Tommasi, Michael Shultz, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Claus Ehrhardt
  • ORGANIC COMPOUNDS AND THEIR USES
    Publication number: 20130022572
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 24, 2013
    Inventors: Trixi BRANDL, Prakash RAMAN, Pascal RIGOLLIER, Mohindra SEEPERSAUD, Oliver SIMIC
  • ArylSulfonamide Based Matrix Metalloprotease Inhibitors
    Publication number: 20120258954
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Application
    Filed: May 29, 2012
    Publication date: October 11, 2012
    Applicant: NOVARTIS AG
    Inventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi